CEN BIOTECH INC (CENB) financial statements (2020 and earlier)

Company profile

Business Address 7405 TECUMSEH ROAD EAST
WINDSOR, ON N8T 1G2
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 385623
Cash and cash equivalents 385623
Total current assets: 385623
Noncurrent Assets
Property, plant and equipment 16715168,292
Long-term investments and receivables 4545  
Due from related parties 4545  
Intangible assets, net (including goodwill) 5,8066,2312,320 
Intangible assets, net (excluding goodwill) 5,8066,2312,320 
Deferred costs  217  
Other undisclosed noncurrent assets   1,695 
Total noncurrent assets: 6,0176,5074,0328,292
Other undisclosed assets 1,2942,429  
TOTAL ASSETS: 7,3159,0214,0948,295
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 7,4694,9293,7151,986
Accounts payable 20793157165
Accrued liabilities 402296841594
Interest and dividends payable 6,8604,5412,7171,228
Debt 13,70511,44419,9259,866
Due to related parties 1,361126375
Other undisclosed current liabilities 1,8733,642(9,009)1,564
Total current liabilities: 24,40820,02714,69413,491
Noncurrent Liabilities
Long-term debt and lease obligation 1,5462,2081,392 
Long-term debt, excluding current maturities 1,5462,2081,392 
Liabilities, other than long-term debt  300  
Due to related parties  300  
Other undisclosed noncurrent liabilities 2,6225,5001,388612
Total noncurrent liabilities: 4,1688,0082,780612
Total liabilities: 28,57628,03617,47414,103
Stockholders' equity
Stockholders' equity attributable to parent, including: (21,261)(19,015)(13,390)(5,808)
Preferred stock   00
Common stock   00
Additional paid in capital 14,3949,11010 
Accumulated deficit (35,655)(28,125)(13,390)(5,808)
Other undisclosed stockholders' equity attributable to parent   (10) 
Other undisclosed stockholders' equity   10 
Total stockholders' equity: (21,261)(19,015)(13,380)(5,808)
TOTAL LIABILITIES AND EQUITY: 7,3159,0214,0948,295

Income statement (P&L) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:   2 
Operating expenses (4,371)(11,614)(5,981)(1,166)
Other undisclosed operating loss   (2) 
Operating loss: (4,371)(11,614)(5,981)(1,166)
Nonoperating expense (3,160)(2,466)(1,601)(121)
Foreign currency transaction gain (loss), before tax 92(89)(48)(121)
Interest and debt expense (431)(336)(288)(1,362)
Net loss: (7,961)(14,417)(7,870)(2,649)
Other undisclosed net income attributable to parent 431336288242
Net loss available to common stockholders, diluted: (7,530)(14,080)(7,582)(2,407)

Comprehensive Income ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (7,961)(14,417)(7,870)(2,649)
Comprehensive loss, net of tax, attributable to parent: (7,961)(14,417)(7,870)(2,649)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: